SMAD3 and neoplasm: ARID1A participates in the TGF-β/BMP-pathway as a tumor suppressor that interacts with p53 regulating cyclin-dependent kinase inhibitor 1A (CDKN1A) and SMAD3 transcription and subsequently tumor growth [71].